Caris Life Sciences (CAI) Total Debt (2024 - 2026)

Caris Life Sciences' Total Debt history runs 3 years deep, the most recent figure standing at $381.6 million for Q1 2026.

• In Q1 2026, Total Debt changed N/A year-over-year to $381.6 million; the TTM figure through Mar 2026 stood at $381.6 million (changed N/A YoY), while the FY2025 annual figure was $379.0 million, changed 0.14% from the prior year.
• Total Debt was $381.6 million for Q1 2026 at Caris Life Sciences, up from $379.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $381.6 million in Q1 2026 to a low of $373.7 million in Q2 2025.
• Historically, Total Debt has averaged $378.1 million across 3 years, with a median of $379.0 million in 2025.
• Biggest YoY gain for Total Debt was 0.14% in 2025; the steepest drop was 0.14% in 2025.
• A 3-year view of Total Debt shows it stood at $379.5 million in 2024, then decreased by 0.14% to $379.0 million in 2025, then grew by 0.68% to $381.6 million in 2026.
• The last three Total Debt figures came in at $381.6 million (Q1 2026), $379.0 million (Q4 2025), and $376.5 million (Q3 2025), per Business Quant data.